The GLP-1 Data Series

Every major trial's headline results in one place — weight loss, completion rates, cardiovascular outcomes, and the gap between on-treatment and intention-to-treat estimates that most presentations don't show.

List prices, net costs after rebates, consumer self-pay, and Medicare negotiated prices — side by side for every drug. Includes PMPM trends over time, the PBM transparency problem, and an interactive cost calculator.

Persistence rates from every published study, from 30 days through 3 years — including why reported 12-month rates range from 10% to 63% depending on the source, and what's actually improved since 2021.

Weight regain data from every trial withdrawal and extension study, plus metabolic parameter rebound. What the evidence says about indefinite treatment — and what that means when 92% of patients stop within 3 years.

The only published real-world analysis found no medical cost offsets — costs actually increased $1,338 per member. How the SELECT trial counterargument falls apart, and what honest ROI modeling looks like.